Amalgamated Bank grew its stake in Alkermes PLC (NASDAQ:ALKS) by 30.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,705 shares of the company’s stock after purchasing an additional 6,743 shares during the quarter. Amalgamated Bank’s holdings in Alkermes PLC were worth $1,664,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of ALKS. BlackRock Inc. raised its position in shares of Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock valued at $602,115,000 after purchasing an additional 10,121,839 shares during the period. Primecap Management Co. CA raised its position in shares of Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock valued at $459,608,000 after purchasing an additional 1,480,273 shares during the period. Janus Capital Management LLC raised its position in shares of Alkermes PLC by 220.0% in the first quarter. Janus Capital Management LLC now owns 1,658,928 shares of the company’s stock valued at $97,045,000 after purchasing an additional 1,140,555 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Alkermes PLC by 40.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,857,077 shares of the company’s stock valued at $167,138,000 after purchasing an additional 820,355 shares during the period. Finally, Fiera Capital Corp bought a new position in shares of Alkermes PLC in the second quarter valued at about $37,717,000. 99.07% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on the stock. ValuEngine raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group LLC set a $69.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, August 25th. BidaskClub lowered shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $62.89.
In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the transaction, the chief accounting officer now owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $58.11, for a total value of $87,165.00. Following the transaction, the director now directly owns 9,500 shares of the company’s stock, valued at approximately $552,045. The disclosure for this sale can be found here. Insiders have sold 18,066 shares of company stock valued at $941,485 in the last three months. 5.34% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/20/alkermes-plc-alks-shares-bought-by-amalgamated-bank.html.
Shares of Alkermes PLC (ALKS) opened at 50.54 on Wednesday. Alkermes PLC has a 1-year low of $41.93 and a 1-year high of $63.40. The firm’s market capitalization is $7.77 billion. The stock has a 50 day moving average of $51.49 and a 200-day moving average of $56.44.
Alkermes PLC (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The firm had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. During the same period in the prior year, the business posted ($0.01) earnings per share. The company’s revenue was up 12.1% on a year-over-year basis. On average, equities analysts expect that Alkermes PLC will post ($0.04) earnings per share for the current year.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.